SALT LAKE CITY, Aug. 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that two abstracts related to LPCN 2101 have been accepted for poster presentation at the 2025 American Epilepsy Society (AES) annual meeting to be held December 5-9 in Atlanta, Georgia. LPCN 2101 is in development for the potential treatment of epilepsy.
AES 2025 Annual Meeting: December 5-9, 2025 | |
Title: | Oral Toxicokinetics of a Bioidentical GABAA Receptor Modulating |
Author: | Joshua C. Weavil, Jonathan Ogle, Min-Jee Goh, Joel Frank, Samuel Akapo, |
Date: | Sunday, December 7, 12:00 PM – 2:00 PM |
Abstract Number: | 2.331 |
Title: | Clinical Pharmacokinetics (PK) and Tolerability of a Novel Oral GABAA |
Author: | Min-Jee Goh, Jonathan Ogle, Joshua C. Weavil, Joel Frank, Samuel Akapo, |
Date: | Monday, December 8, 2025, 12:00 PM – 1:45 PM |
Abstract Number: | 3.354 |
Abstracts are embargoed from the AES online abstract database until Monday, November 24, 2025.
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.
Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for obesity management, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of metabolic dysfunction-associated steatohepatitis (MASH). TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
| Last Trade: | US$2.63 |
| Daily Change: | -0.07 -2.42 |
| Daily Volume: | 29,121 |
| Market Cap: | US$14.230M |
September 30, 2025 June 26, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
